Cargando…
非小细胞肺癌中驱动基因状态与免疫治疗相关性的研究进展
In recent years, the checkpoint inhibitors targeted programmed cell death 1 (PD-1) and its ligand 1 (PD-1 ligand, PD-L1) achieved landmark significance in treating a variety of cancers including non-small cell lung cancer (NSCLC). However, current immunotherapy is not precise enough, only 15%-20% of...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500499/ https://www.ncbi.nlm.nih.gov/pubmed/31014442 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.06 |